Warning! GuruFocus detected
1 Severe warning sign
with 7AY1.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Actinium Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US00507W1071
Description
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 45.97 | |||||
| Equity-to-Asset | 0.47 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -6.29 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -2 | |||||
| 3-Year FCF Growth Rate | 0.3 | |||||
| 3-Year Book Growth Rate | -27.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 17.21 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 242.3 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 79.26 | |||||
| 9-Day RSI | 71.47 | |||||
| 14-Day RSI | 65.15 | |||||
| 3-1 Month Momentum % | 4.3 | |||||
| 6-1 Month Momentum % | -31.95 | |||||
| 12-1 Month Momentum % | -85.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.25 | |||||
| Quick Ratio | 10.25 | |||||
| Cash Ratio | 10.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -16.4 | |||||
| Shareholder Yield % | -68.12 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -55504.94 | |||||
| Net Margin % | -50512.35 | |||||
| FCF Margin % | -43050 | |||||
| ROE % | -99.37 | |||||
| ROA % | -47.5 | |||||
| ROIC % | -1275.72 | |||||
| 3-Year ROIIC % | -1618.8 | |||||
| ROC (Joel Greenblatt) % | -1688.03 | |||||
| ROCE % | -57.94 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 551 | |||||
| PB Ratio | 1.35 | |||||
| Price-to-Tangible-Book | 1.26 | |||||
| EV-to-EBIT | 0.64 | |||||
| EV-to-Forward-EBIT | -0.12 | |||||
| EV-to-EBITDA | 0.65 | |||||
| EV-to-Forward-EBITDA | -0.12 | |||||
| EV-to-Revenue | -354.78 | |||||
| EV-to-Forward-Revenue | 5246.5 | |||||
| EV-to-FCF | 0.95 | |||||
| Price-to-GF-Value | 2.05 | |||||
| Price-to-Net-Current-Asset-Value | 1.35 | |||||
| Price-to-Net-Cash | 1.4 | |||||
| Earnings Yield (Greenblatt) % | 157.13 | |||||
| FCF Yield % | -71.66 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Actinium Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.074 | ||
| EPS (TTM) (€) | -1.274 | ||
| Beta | -0.25 | ||
| 3-Year Sharpe Ratio | -0.28 | ||
| 3-Year Sortino Ratio | -0.39 | ||
| Volatility % | 70.25 | ||
| 14-Day RSI | 65.15 | ||
| 14-Day ATR (€) | 0.052303 | ||
| 20-Day SMA (€) | 1.07695 | ||
| 12-1 Month Momentum % | -85.69 | ||
| 52-Week Range (€) | 0.993 - 9.11 | ||
| Shares Outstanding (Mil) | 31.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Actinium Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Actinium Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Actinium Pharmaceuticals Inc Frequently Asked Questions
What is Actinium Pharmaceuticals Inc(STU:7AY1)'s stock price today?
The current price of STU:7AY1 is €1.27. The 52 week high of STU:7AY1 is €9.11 and 52 week low is €0.99.
When is next earnings date of Actinium Pharmaceuticals Inc(STU:7AY1)?
The next earnings date of Actinium Pharmaceuticals Inc(STU:7AY1) is 2025-04-25 Est..
Does Actinium Pharmaceuticals Inc(STU:7AY1) pay dividends? If so, how much?
Actinium Pharmaceuticals Inc(STU:7AY1) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers